• Secured $3.8m capital raise to support growth initiatives
• Entered distribution partnership with Tobii for NeuroNode
• Completed acquisition of NeuroBounce for sports performance

Control Bionics Limited (ASX: CBL) announced its Quarterly Activities Report and Appendix 4C for the quarter ended 31 December 2025. Key highlights include a significant capital raise of over $3.8 million (before costs) to support the company's growth initiatives, the completion of a distribution partnership with Tobii, the world's largest provider of Augmentative and Assistive Communication (AAC) solutions, and the acquisition of Neuro Elite Athletics ('NeuroBounce') to establish a dedicated platform for the company's Sports Performance program. The company also announced that it had become one of the first organisations globally to integrate with Apple's BCI (Brain Computer Interface) protocol, further strengthening its position in the non-invasive neurotechnology space. Momentum continued with the NeuroStrip platform, with multiple organisations in the United States and Australia now actively utilizing the technology across sports performance and rehabilitation settings. The company also commenced scaled manufacturing of NeuroStrip devices and consumables during the quarter to support growing demand. Cash receipts for the quarter totalled $1.4 million, consistent with the corresponding period in FY25, with revenue impacted by ongoing delays in NDIS approvals in Australia, an issue affecting the broader assistive technology sector. The company remains focused on five key strategic priorities for 2026, including achieving profitability in core markets, scaling the NeuroNode business, expanding the NeuroStrip platform, accelerating growth through strategic partnerships and acquisitions, and building a high-performance organisation to support sustainable long-term growth.

The company reported cash receipts of $1.4 million for the quarter, consistent with the corresponding period in FY25. No other high-importance, price-sensitive forward-looking financial metrics were provided.

Control Bionics is focused on five key strategic priorities for 2026, including achieving profitability in core markets, scaling the NeuroNode business, expanding the NeuroStrip platform, accelerating growth through strategic partnerships and acquisitions, and building a high-performance organisation to support sustainable long-term growth.